William Sikov MD
Breast Cancer, Gastrointestinal Cancer, Hematologic Oncology
Associate Professor of Medicine, Brown University
Join to View Full Profile
1 Blackstone Street2ND floorProvidence, RI 02903
Phone+1 401-453-7520
Fax+1 401-453-7785
Dr. Sikov is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1989
UPMC Medical EducationResidency, Internal Medicine, 1982 - 1985
Yale School of MedicineClass of 1982
Certifications & Licensure
RI State Medical License 1989 - 2026
MA State Medical License 1986 - 2025
PA State Medical License 1983 - 1990
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse Start of enrollment: 2007 Nov 01
- Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer Start of enrollment: 2008 Feb 01
- Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
- Join now to see all
Publications & Presentations
PubMed
- Reply to the Letter to the Editor 'Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple-negative breast cancer' by A. Okine...C E Geyer Jr, W M Sikov, S Loibl
Annals of Oncology. 2022-07-01 - 90 citationsLong-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow...C E Geyer, W M Sikov, J Huober, H S Rugo, N Wolmark
Annals of Oncology. 2022-04-01 - ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40...Anna Weiss, Jordan Campbell, Karla V Ballman, William M Sikov, Lisa A Carey
Annals of surgical oncology. 2021-12-01
Journal Articles
- Association of Immunophenotype with Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast CancerCharles E Geyer, William M Sikov, JAMA Oncology
Lectures
- CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TN...2019 ASCO Annual Meeting - 6/1/2019
Other
- Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosisSikov WM
http://www.uptodate.com/contents/neoadjuvant-systemic-therapy-for-breast-cancer-response-subsequent-
UpToDate, Wolters Kluwer Health - 2013-03-20 - Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic optionsSikov WM, Wolff AC
http://www.uptodate.com/contents/neoadjuvant-therapy-for-breast-cancer-rationale-pretreatment-evalua
UpToDate, Wolters Kluwer Health - 2012-09-17
Press Mentions
Women & Infants Doctor to Appear on ‘Jeopardy!’September 26th, 2019
Adjuvant Pertuzumab in HER2-Positive Breast Cancer: Value yet to Be DemonstratedOctober 10th, 2017
Pathologic Complete Response Best Predictor in Triple-Negative PrognosisFebruary 10th, 2016- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
